Evolocumab (Repatha®) for the treatment of hypercholeresterolaemia

The National Health Care Institute issued a package advice on the medicinal product evolocumab (Repatha®) for the treatment of hypercholeresterolaemia. The National Health Care Institute advises the Minister of WVS not to alter the reimbursement condition for evolocumab (Repatha®) for the time being; the current List 2 condition can remain unchanged. As soon as the update of the Multidisciplinary Guidelines on CVRM are available, we will resume establishing our advice on the application to alter the specific conditions.